Work

A phase I study of the combination of ruxolitinib and the ERK1/2 inhibitor ulixertinib in previously treated myelofibrosis patients.

Year: 2025

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2025-5606

Authors: Chi-Joan How, Gabriela Hobbs, Aaron Gerds, Andriy Derkach, Emily Burton, Aurora Duran, Katherine Kan, Michael Mauro, Brian Chernak, Tamanna Haque, Raajit Rampal

Institutions: Brigham and Women's Hospital, Massachusetts General Hospital, Cleveland Clinic, Memorial Sloan Kettering Cancer Center

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4417012705

Cites:

Cited by:

Related to: